soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣, ⁣, #ACC25 #Cardiology #ClinicalTrials #NEJM Oral Semaglutide Reduces CV Events

She added: We may get some answers from that, from real world data, but I think it would be such an expensive and huge undertaking to show this preventative aspect, we would have to think about how to fund that. Dr Jorge Plutzky, lead study author and director of preventive cardiology at Brigham and Womens Hospital at Harvard Medical School in the US, said: Semaglutide 2.4mg is the only GLP-1 to have shown these early, rapid effects on heart disease, with benefits seen in the order of months, not years underscoring its important role in clinical practice. He added: Our findings reveal an early separation in the treatment effect of semaglutide that occurs even without a significant amount of weight lost and prior to full semaglutide titration

Lifestyle and Nutritional Guidance for Lasting Results Sustainable weight loss isnt just about medication

Appetite Control : Semaglutide helps reduce hunger and cravings, making it easier to stick to a healthy diet and avoid overeating

Most patients benefit from continued therapy, even at lower maintenance doses, to sustain weight loss and prevent metabolic creep back toward baseline